SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

NovoCure Ltd. – ‘8-K’ for 4/29/21

On:  Thursday, 4/29/21, at 6:08am ET   ·   For:  4/29/21   ·   Accession #:  1645113-21-62   ·   File #:  1-37565

Previous ‘8-K’:  ‘8-K’ on / for 4/13/21   ·   Next:  ‘8-K’ on 6/11/21 for 6/9/21   ·   Latest:  ‘8-K’ on / for 3/27/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/29/21  NovoCure Ltd.                     8-K:2,9     4/29/21   13:321K

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     26K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     66K 
 9: R1          Document and Entity Information Document            HTML     46K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- nvcr-20210429_htm                   XML     21K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.CAL  XBRL Calculations -- nvcr-20210429_cal               XML      7K 
 5: EX-101.DEF  XBRL Definitions -- nvcr-20210429_def                XML      9K 
 6: EX-101.LAB  XBRL Labels -- nvcr-20210429_lab                     XML     68K 
 7: EX-101.PRE  XBRL Presentations -- nvcr-20210429_pre              XML     33K 
 3: EX-101.SCH  XBRL Schema -- nvcr-20210429                         XSD     11K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
13: ZIP         XBRL Zipped Folder -- 0001645113-21-000062-xbrl      Zip     23K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C: 
  nvcr-20210429  
 i 0001645113 i false00016451132021-04-262021-04-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM  i 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 i April 29, 2021
Date of Report (date of earliest event reported)

 i NovoCure Limited
(Exact name of registrant as specified in its charter)
 i Jersey
 i 001-37565
 i 98-1057807
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
 i No. 4 The Forum, Grenville Street
 i St. Helier
 i Jersey
 i JE2 4UF
(Address of Principal Executive Offices)
(Zip Code)
+ i 44 (0) 15  i 3475 6700
Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 i  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 i  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
 i Ordinary Shares, no par value i NVCR i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o




Item 2.02     Results of Operations and Financial Condition.

On April 29, 2021, the Company issued a press release announcing certain financial results for the quarter ended
March 31, 2021. A copy of the press release is attached as Exhibit 99.1.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovoCure Limited
(Registrant)

Date: April 29, 2021


By: /s/ Ashley Cordova  
Name: Ashley Cordova
Title: Chief Financial Officer


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:4/29/2110-Q
3/31/2110-Q,  4
 List all Filings 
Top
Filing Submission 0001645113-21-000062   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 2:35:29.2pm ET